Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
NCT02928263
·
clinicaltrials.gov ↗
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Business objectives have changed
Conditions
Renal Cell Carcinoma
Interventions
OTHER:
Non-Interventional
Sponsor
Bristol-Myers Squibb